TC Biopharm announces partnership with CareDx

TC BioPharm (TCBP) announced a partnership with CareDx (CDNA) who will perform pharmacokinetic analysis using its AlloCellsolution in the ACHIEVE clinical trial. The ACHIEVE clinical trial is an adaptive, open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB008, an allogeneic gamma delta T cell therapy for patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome. CareDx is a leading precision medicine company focused on discovering, developing, and commercializing healthcare solutions for transplant patients and caregivers. CareDx’s AlloCell test, a sensitive solution for pharmacokinetic monitoring of allogeneic immune and stem cell therapies, will be used to evaluate the expansion and persistence of TCB008 in patients enrolled in the ACHIEVE trial.